Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies

Area of Science:

• Oncology
• Bone Biology
• Molecular Modeling

Background:

• Osteolytic bone damage is a significant complication of metastatic cancer, often inadequately treated by current therapies like bisphosphonates due to side effects and limited efficacy.
• Receptor activator of NF-κB ligand (RANKL) signaling is crucial for osteoclast activation and bone resorption, making it a key therapeutic target.
• Osteoprotegerin (OPG) inhibits RANKL but also binds TNF-related apoptosis-inducing ligand (TRAIL), potentially causing tumor resistance to apoptosis.

Purpose of the Study:

• To develop OPG variants that inhibit osteoclastogenesis without compromising anti-tumor apoptosis.
• To engineer OPG mutants by rationally designing based on structural homology and domain identification.

Main Methods:

• Structural homology modeling was used to identify key interaction domains between OPG, TRAIL, and its receptor DR5.
• OPG mutants were designed, purified, and characterized in vitro and in vivo.
• The efficacy of OPG variants in reducing osteoclast damage and their effect on tumor apoptosis were assessed.

Main Results:

• Engineered OPG variants were successfully developed that retain RANKL binding capabilities.
• These OPG variants effectively decreased osteoclast-mediated bone damage.
• Importantly, the OPG variants did not inhibit the TRAIL-induced apoptosis pathway in tumor cells.

Conclusions:

• Novel OPG variants lacking TRAIL binding but retaining RANKL binding were created.
• These OPG variants show potential for therapeutic application in managing osteolytic bone disease in cancer patients.
• This research opens new avenues for targeting bone remodeling in osteolytic malignancies.